Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin.57, 43–66 (2009).
   Web of Science ®Google Scholar
• Benson AB, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol.22(16), 3408–3419 (2004).
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N. Engl. J. Med.350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Mariotto AB, Feuer E, Brown ML. Projections of the costs associated with colorectal cancer care in the United States, 2000–2020. Health Econ.17(8), 947–959 (2008).
   PubMed Web of Science ®Google Scholar
• Kerrigan M, Howlader N, Mandelson MT et al. Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med. Care43(10), 1043–1048 (2005).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine vs intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol.19, 2282–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol.19, 4097–4106 (2001).
   PubMed Web of Science ®Google Scholar
• Twelves C, Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, Phase III trials. Eur. J. Cancer38(Suppl. 2), 15–20 (2002).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol.26(12), 2006–2012 (2008).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized Phase III noninferiority study. Ann. Oncol.19(10), 1720–1726 (2008).
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352(26), 2696–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Schmoli HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol.25(1), 102–109 (2007).
   PubMed Web of Science ®Google Scholar
• Haller D, Tabernero J, Maroun J et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Eur. J. Cancer Suppl.7(3), 4 (2009).
   Google Scholar
• Mayer RJ. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J. Clin. Oncol.25(27), 4165–4167 (2007).
   PubMed Web of Science ®Google Scholar
• Chu E, Cartwright TH. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. J. Clin. Oncol.26(13), 2224–2225 (2008).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Schmoll HJ, Cutsem EV. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. J. Clin. Oncol.26(13), 2226–2227 (2008).
   PubMed Web of Science ®Google Scholar
• Almond J, Ralston S. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br. J. Cancer96(9), 1489 (2007).
   PubMed Web of Science ®Google Scholar
• Ferro SA, Myer BS, Debra A, Wolff et al. Variation in the cost of medications for the treatment of colorectal cancer. Am. J. Manag. Care14(11), 717–725 (2008).
   PubMed Web of Science ®Google Scholar
• Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J. Manag. Care Pharm.12(7), 570–577 (2006).
   PubMed Web of Science ®Google Scholar
• Gorner M, Riemer-Hommel P. Adjuvant chemotherapy for colon cancer – analysis of treatment costs from the perspective of statutory sickness funds. Z. Gastroenterol.46(7), 681–688 (2008).
   PubMed Web of Science ®Google Scholar
• Chu E, Schulman KL, Zelt S, Song X. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer1115(7), 1412–1423 (2009).
   Google Scholar
• Shiroiwa T, Fukuda T. Cost–effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin. Therapeutics29(10), 2256–2267 (2007).
   PubMed Web of Science ®Google Scholar
• Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer115, 2081–2091 (2009).
   PubMed Web of Science ®Google Scholar
• Twelves C. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin. Colorectal Cancer6(4), 278–287 (2006).
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Sundararajan V, Grann VR et al. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging21(2), 113–133 (2004).
   PubMed Web of Science ®Google Scholar
• Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics25(7), 537–562 (2007).
   PubMed Web of Science ®Google Scholar
• Krol M, Koopman M, Uyl-de Groot C, Punt CJA. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin. Pharmacother.8(9), 1313–1328 (2007).
   PubMed Web of Science ®Google Scholar
• Hieke K, Kleeberg UR, Stauch M, Grothey A. Costs of treatment of colorectal cancer in different settings in Germany. Eur. J. Health Econ.5(3), 270–273 (2004).
   PubMedGoogle Scholar
• Grothey A, Kleeberg UR, Stauch M, Hieke K. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. Z. Gastroenterol.43(2), 155–161 (2005).
   PubMed Web of Science ®Google Scholar
• Jansman FGA, Postma MJ, van Hartskamp D, Willemse PHB, Brouwers JRBJ. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin. Ther.26(4), 579–589 (2004).
   PubMed Web of Science ®Google Scholar
• Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost–effectiveness of capecitabine and tegafur with uracil for the treatment of metastataic colorectal cancer: systematic review and economic evaluation. Health Technol. Assess.7(32), 1–93 (2003).
   PubMedGoogle Scholar
• Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br. J. Cancer95, 27–34 (2006).
   PubMed Web of Science ®Google Scholar
• Lapatriello S, Amoroso D, Donati S et al. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine. Eur. J. Cancer44(17), 2615–2622 (2008).
   PubMed Web of Science ®Google Scholar
• Caponero R, Ribeiro Rde A, Santos E, Cirrincione A, Saggia M. Medical resource use and cost of different first-line treatments for metastatic colorectal cancer in Brazil. J. Med. Econ.11(2), 311–325 (2008).
   PubMedGoogle Scholar
• Shiroiwa T, Fukuda T, Tsutani K. Cost–effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br. J. Cancer101(1), 1195–1201 (2009).
   Google Scholar
• Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br. J. Cancer94, 1122–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Tech. Assess.10(41), 1–153 (2006).
   Web of Science ®Google Scholar
• Eggington S, Tappenden P, Pandor A et al. Cost–effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br. J. Cancer95(9), 1195–1201 (2006).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Tilleul P, Ychou M et al. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology72(3–4), 248–252 (2007).
   PubMed Web of Science ®Google Scholar
• Di Costanzo F, Ravasio R, Sobrero A et al. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes’ C colon cancer. Clin. Drug Invest.28(10), 645–655 (2008).
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Fragoulakis V, Pectasides D, Fountzilas G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin.25(3), 797–805 (2009).
   PubMed Web of Science ®Google Scholar
• Chu E, Shi N, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology77, 244–253 (2009).
   PubMed Web of Science ®Google Scholar
• Goerner M, Riemer-Hommel P. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer. Onkologie32(11), 647–652 (2009).
   PubMedGoogle Scholar
• Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol.13, 566–575 (2002).
   PubMed Web of Science ®Google Scholar
• Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, Phase III trial. Ann. Oncol.14, 1735–1743 (2003).
   PubMed Web of Science ®Google Scholar
• Garrison L, Patel KK, Sengupta N, Green J, Best JH. The cost–effectiveness of capecitabine as adjuvant oral chemotherapy for Duke’s C colon cancer. Value Health8(3), 345 (2005).
   Google Scholar
• Garrison L, Cassidy J, Saleh M et al. Cost comparison of XELOX compared to FOLFOX-4 with or without bevacizumab in metastatic colorectal cancer: XELOX vs. FOLFOX-4 bevacizumab. J. Clin. Oncol.25(Suppl. 188) (2007) (Abstract 4083).
   Google Scholar
• Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force Report. Value Health10(5), 326–335 (2007).
   PubMed Web of Science ®Google Scholar
• Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health12(8), 1118–1123 (2009).
   PubMed Web of Science ®Google Scholar
• Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JDF, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J. Natl Cancer Inst.101(20), 1412–1422 (2009).
   PubMed Web of Science ®Google Scholar